about
HER2 expression in cervical cancer as a potential therapeutic targetCAR T Cell Therapy: A Game Changer in Cancer TreatmentConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsAmplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodinationCombination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivoHER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging.Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.HER2 in solid tumors: more than 10 years under the microscope; where are we now?Cancer stratification by molecular imaging.Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyHigh contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets.Targeting breast carcinoma with radioiodinated anti-HER2 NanobodyCombinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.Molecular imaging probes for diagnosis and therapy evaluation of breast cancerStatus of HER-2 gene amplification in breast cancers from Native American womenTargeted therapies in the management of metastatic bladder cancerExpression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes.A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity.HER2 mutations in Chinese patients with non-small cell lung cancer.Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studiesConformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells.The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel.TOP2A amplification and overexpression in hepatocellular carcinoma tissues.Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin.HER2 expression in gastric cancer in Indian population--an immunohistochemistry and fluorescence in situ hybridization study.Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer.Circulating human epidermal growth factor receptor 2 (HER2) is associated with hyperglycaemia and insulin resistance.Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report.Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental fish study.SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors.TFF3 and HER2 expression and their correlation with survival in gastric cancer.Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer
P2860
Q24792559-B7F433D2-438E-472A-89A7-772C456C662DQ26822769-7D6868DC-B47F-424C-B89F-A032FDFB4E8BQ26830569-698B762D-BF93-4B25-A067-15D5E39C0EF6Q34554455-934BE2CC-3712-416E-9965-7B7860A75547Q34718122-ABB068FD-F34B-405D-AD6C-62405759113AQ34787422-BE1BEE0B-5E45-45ED-AAE0-9EDE58B80A7DQ34974682-ECECA0B0-F746-4998-9B92-BAC4768BE3FEQ35005791-8E251C94-BC06-4B36-B226-9AAC6D23DBE8Q35211263-CFB96CDB-ECAF-45A7-A031-955052BC0DBBQ35380664-528325E0-44CC-4A41-B773-F703E77F4F9DQ36105964-7F7AA396-37F8-44C9-B5FB-BCDC223D6177Q36116250-67170232-D5FE-494A-B33C-8A755FE9DF09Q36211450-2EDABB1C-AAAB-4E5F-9F05-6098E7B54608Q36334889-D92B6517-2636-48D3-9CF2-F39B5D3C8A4FQ36552076-C3D3E495-F28F-49DB-8B9E-87F6320E7D18Q36610604-318C4582-4E30-4185-8C1B-2D9D348AE16DQ36692448-FB876978-EE6E-4106-B31C-F76C961EFD33Q37003086-6796FFD0-BCB5-4724-A722-93CAA9EA356FQ37290448-FD22B583-1850-426A-8357-30DA9E889FF3Q37429878-2FB1A968-BCE6-471C-B43D-18FBF68337BAQ37694673-0C75834C-FA41-47C2-B5B2-762AE930DFF8Q37718501-AEE050C1-201F-44FE-A94B-D70CB9F80E5FQ37850379-FF9EE03F-5799-4C63-9DBE-04C355325B96Q39200327-24244224-FBF8-44DA-B83C-DCB988FD6A5BQ40499571-A9F876BC-34E6-43E5-8C48-2B62164ED815Q41302727-8B057056-8FDC-4CD9-8BA1-B02DF64CEE17Q41996754-318E1847-510E-4224-8CF7-18E2534F27CAQ42180761-C5633E74-3CEC-4C6A-AD9C-E6D6F3EBE112Q42290643-0C8345DD-E5DA-4B97-8E02-E7AA7768A664Q43511214-C17265E2-D0AE-4A64-BFB5-134D882DA715Q44068928-82A99162-D58E-4348-93FE-43F36A18AD1CQ46215779-23816477-E21A-46AE-B832-039CBF156729Q47137872-06AC3B46-E3FD-4AB5-8BDD-5B05CB9912AEQ50068024-10C4456B-A5A4-486E-AB66-053231BBF409Q50878559-6892DCAB-DF81-4B61-A839-3665E4821560Q50990911-5002C257-C318-44CF-96A7-E5A4FB1B349FQ53667030-F763E6D2-0F58-487B-BCA4-7007953938C8Q57295430-4547C14E-C9BB-480A-9874-005DFAE6F743
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Targeting HER2 in other tumor types.
@ast
Targeting HER2 in other tumor types.
@en
Targeting HER2 in other tumor types.
@nl
type
label
Targeting HER2 in other tumor types.
@ast
Targeting HER2 in other tumor types.
@en
Targeting HER2 in other tumor types.
@nl
prefLabel
Targeting HER2 in other tumor types.
@ast
Targeting HER2 in other tumor types.
@en
Targeting HER2 in other tumor types.
@nl
P2093
P356
P1433
P1476
Targeting HER2 in other tumor types.
@en
P2093
P356
10.1093/ANNONC/12.SUPPL_1.S81
P478
12 Suppl 1
P577
2001-01-01T00:00:00Z